Multiply Labs Builds the Robotic Biomanufacturing Stack

Multiply Labs is building physical AI for one of biotechnology's least glamorous and most consequential problems: making advanced therapies reliably, repeatedly, and at commercial scale. The San Francisco company builds robotic biomanufacturing infrastructure for cell and gene therapies, antibodies, viral vectors, and mRNA.

Founded in 2016, Multiply Labs is led by Co-Founder and CEO Fred Parietti and Co-Founder and CSO Alice Melocchi. The company sits at an unusual intersection of robotics, pharmaceutical science, cleanroom operations, and manufacturing software. That combination matters because a therapy can be scientifically brilliant and still fail to reach patients if the factory cannot reproduce it fast enough, cheaply enough, or consistently enough.

Multiply Labs matters now because the advanced-therapy market is moving from discovery excitement into manufacturing reality. Its newly announced $75M Series B, which brings total capital raised since 2016 to more than $100M, is intended to expand manufacturing capacity and product, engineering, regulatory, and commercial work.

From MIT Prototypes to Robotic Biomanufacturing

The founding story began around MIT, where Melocchi was working in pharmaceutical manufacturing and Parietti was building robots. MIT News reported that Melocchi saw a possible bridge between the two disciplines, while Parietti assembled an early prototype in the kitchen of his Cambridge apartment. The first products centered on personalized capsules, but the larger opportunity became clear: pharmaceutical companies needed smaller, more flexible, more automated production systems.

That history explains the company's current design philosophy. Multiply Labs does not ask manufacturers to abandon every instrument and process they have already validated. Its robots are designed to operate existing GMP equipment, which can reduce the burden of process transfer and preserve the work already embedded in manufacturing protocols.

The strategic move is less cinematic than discovering a new molecule, but it may be just as important. Biotechnology has spent decades getting better at inventing therapies. The factory floor is now being asked to catch up.

How the Multiply Labs Robotic Cluster Works

The Multiply Labs robotic cluster combines four robotic arms with as many as 24 modular instrument towers in a footprint under 600 square feet. The company says the system can automate more than 50 unit operations, including cell counting, centrifugation, media exchange, sample collection, bag transfers, and incubator loading.

A no-code Process Creator App lets scientists define and adjust manufacturing sequences. The orchestration software coordinates the robotic arms, records sensor data and operator actions, and feeds electronic records into existing quality workflows. Multiply Labs says the system supports 21 CFR Part 11 compliant electronic records and signatures.

The value proposition is not robots for the sake of robots. It is repeatability. Manual cleanroom work depends on skilled people performing long sequences of precise actions under sterile conditions. Every handoff creates another chance for variability, contamination, delay, or incomplete documentation. A robotic system can execute the same sequence continuously while capturing a richer record of what happened.

Multiply Labs reports that its system can automate 90% of cleanroom steps, increase throughput per square foot by up to 100x, and reduce cost per dose by 74%. Those are company-reported figures, but they frame the scale of the manufacturing problem the company is trying to solve.

Scientific Evidence Behind the Platform

Multiply Labs has also put part of its thesis into the scientific record. A 2024 Cytotherapy paper indexed by PubMed evaluated a robotic cluster built around industry-standard cell therapy equipment. In a proof of concept involving human CD8+ T-cell expansion, the robotic cultures produced comparable cell yield, viability, and identity to manually handled cultures while maintaining sterility.

The study does not settle every commercial or regulatory question. Many authors were current or former Multiply Labs employees, and the paper discloses equity, advisory, and sponsored-research relationships. That context matters. The useful signal is narrower and still meaningful: the company demonstrated, in a peer-reviewed setting, that robotic execution could reproduce important outputs of a manual cell-manufacturing process.

For a sector that often sells the future with a rendering and a confident adjective, actual process data is refreshing.

Partners, Customers, and the Existing Factory Floor

Multiply Labs lists AstraZeneca, Legend Biotech, and Kyverna Therapeutics as announced collaborations. It names NVIDIA and Universal Robots as technology partners and identifies Thermo Fisher Scientific, Charles River, Wilson Wolf, GenScript, Fedegari, Cytiva, and Akron Bio as instrument partners.

That network illustrates the company's practical advantage. Biomanufacturing is not a greenfield software market where a new vendor can replace the stack over a weekend. It is a regulated environment filled with specialized equipment, validated workflows, quality controls, and years of institutional knowledge. Multiply Labs is positioning its robotic layer around that reality.

The company's 2026 funding round also links capital to execution. The $75M Series B was led by Dr. Patrick Soon-Shiong with NantWorks and included strategic and financial investors. The point is not merely that more money arrived. It is that the next phase involves manufacturing capacity, regulatory work, product development, and commercial delivery, the expensive middle where ambitious biotech infrastructure either becomes dependable or becomes a demo.

Leadership and the Team Scaling the System

Fred Parietti leads Multiply Labs as Co-Founder and CEO, while Alice Melocchi leads scientific work as Co-Founder and CSO. Current company materials also identify Enrico Racca as Chief Supply Chain & Manufacturing Officer, Manny Guerrero as CFO, and Kevin Liu as VP, Business Ops & People.

The leadership mix reflects the product itself. Robotics hardware, software, pharmaceutical process science, supply chain, manufacturing, finance, and people operations all have to move together. A robot that performs beautifully in a lab but cannot be built, serviced, documented, or integrated into a regulated workflow is still a science project.

The Multiply Labs careers page says the company is hiring roboticists, scientists, and engineers in San Francisco. That hiring is best read as a market signal. Multiply Labs is staffing the transition from technical validation and partner deployments toward a larger commercial operating system for advanced-therapy manufacturing.

Why Multiply Labs Matters Now

The larger shift is simple: biological innovation is outrunning the machinery used to manufacture it. Advanced therapies can require individualized or small-batch production, intricate sterile handling, constant monitoring, and perfect traceability. Those demands do not fit comfortably inside factory models built for conventional drugs and large batches.

Multiply Labs is betting that the answer is a flexible robotic layer that learns a manufacturer's process, works with existing instruments, and scales by adding clusters. If that architecture holds up across more therapies and commercial deployments, the company could help turn biomanufacturing from a constraint into an expandable capability.

The robots are the visible part. The more important product may be trust: trust that the process ran the same way, that every action was recorded, that throughput can rise without multiplying complexity, and that more of the therapies discovered in laboratories can survive the trip to the factory floor.